242 results on '"Metzgeroth, G"'
Search Results
2. 5-AZACYTIDINE IN COMBINATION WITH A NOVEL PAN-LYSYL OXIDASE INHIBITOR SYNERGISTICALLY RESTORES ERYTHROPOIESIS IN MYELODYSPLASTIC MALIGNANCIES
3. Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: AUGMENTED ACTIVITY OF THE ALVOCIDIB AND 5-AZACYTIDINE COMBINATION IN MYELODYSPLASTIC NEOPLASMS IS ASSOCIATED WITH THE PRESENCE OF ASXL1 MUTATIONS
4. P103 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: AUGMENTED ACTIVITY OF THE ALVOCIDIB AND 5-AZACYTIDINE COMBINATION IN MYELODYSPLASTIC NEOPLASMS IS ASSOCIATED WITH THE PRESENCE OF ASXL1 MUTATIONS
5. P047 - Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): OPTIMIZATION OF MDS PATIENT-DERIVED XENOGRAFT (PDX) MODELS BY COMPARISON OF NSG AND NBSGW MICE
6. O12 - 5-AZACYTIDINE IN COMBINATION WITH A NOVEL PAN-LYSYL OXIDASE INHIBITOR SYNERGISTICALLY RESTORES ERYTHROPOIESIS IN MYELODYSPLASTIC MALIGNANCIES
7. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis
8. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia
9. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
10. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis
11. S169: CLINICAL AND MOLECULAR MARKERS FOR PREDICTING RESPONSE TO ROMIPLOSTIM TREATMENT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES
12. Eisenmangelanämie und Anämie der chronischen Erkrankungen
13. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event
14. O15 - Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: BONE MARROW DERIVED STROMAL CELLS FROM MYELODYSPLASTIC SYNDROMES ARE ALTERED BUT NOT CLONALLY MUTATED IN VIVO
15. O02 - Topic: AS08-Treatment/AS08e-New developments - Preclinical studies: A PRE-CLINICAL PATIENT-DERIVED XENOGRAFT MODEL OF MYELODYSPLASTIC SYNDROMES DEMONSTRATES EFFICACY AND SAFETY OF ELTROMBOPAG
16. Topic: AS08-Treatment/AS08e-New developments - Preclinical studies
17. Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche
18. BCR-ABL-negative myeloproliferative Neoplasien
19. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase
20. The severity of FIP1L1–PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus
21. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma
22. Cytogenetic response to prior treatment with interferon-α is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia
23. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon α
24. Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea
25. Auer rod-like inclusions in multiple myeloma
26. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation
27. Pattern of organ involvement in eosinophilia-associated disorders: V698
28. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany
29. Critical evaluation of current WHO diagnostic criteria for aggressive systemic mastocytosis: V762
30. Selected Abstract Hepatoid adenocarcinoma of the peritoneal cavity-differential diagnosis to hepatocellular carcinoma as established by immunotyping: V48
31. Diagnostic accuracy of cytology and immunocytology in carcinomatous effusions
32. Intestinal-type adenocarcinoma situated in the nasopharynx
33. Clinical and Molecular Features of FIP1L1-PDGFRA Positive Hematologic Disorders Associated with Eosinophilia: O360
34. Do hepatocellular carcinomas express TuM2-PK?: P778
35. Simultaneous appearance of AML and CLL: P569
36. Multilobated nuclei in Waldenströmʼ macroglobulinaemia
37. Favourable survival of cytogenetic IFN-responders after allogeneic stem cell transplantation (SCT) in chronic myeloid leukaemia (CML): 625
38. Epidemiology of chronic myeloid leukemia (CML) and other chronic myeloproliferative disorders in a representative area in Germany: 613
39. Evaluation of haematopoetic recovery after autologous blood stem cell transplantation by soluble transferrin receptor: 346
40. Is TuM2-PK able to discriminate reactive and malignant mesothelial cells?: 280
41. Waldenstrom macroglobulinemia associated with multilobated nuclei: 207
42. A case of systemic alveolar rhabdomyosarcoma mimicking haematological neoplasia: 134
43. Cerivastatin significantly inhibits bone marrow colony growth from patients with CML chronic phase: 107
44. Randomized comparison of Interferon/Hydroxyurea vs Hydroxyurea monotherapy in chronic myeloid leukemia (CML-Study II): 19
45. Selektive Hemmung von Tyrosinkinasen als neues therapeutisches Prinzip in der Onkologie
46. Interlaboratory comparison of a KIT D816V detection assay in patients with systemic mastocytosis by chip-based digital PCR
47. S1611 MARS: MUTATION-ADJUSTED RISK SCORE FOR ADVANCED SYSTEMIC MASTOCYTOSIS
48. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasm with eosinophilia
49. Erythroferrone (ERFE) and Growth Differentiation Factor 15 (GDF15) Are Overexpressed in Erythroprogenitor Cells of MDS Patients and Associated with Survival
50. CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME ON IMATINIB IN PATIENTS WITH MYELOID/LYMPHOID NEOPLASMS AND ASSOCIATED PDGFRB FUSION GENES IN CHRONIC OR BLAST PHASE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.